ReviewClinical kidney journal2025
Ten tips on how to deal with calciphylaxis patients.
Review in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Calciphylaxis complicated by NDM-1-producing Pseudomonas aeruginosa: first experience with cefepime-zidebactam alongside phage therapy in the USA.The Lancet. Infectious diseases · 2026Review
- Calciphylaxis Mimicry in End-Stage Renal Disease: Acute Limb Ischemia From Calcific Peripheral Arterial Disease.Cureus · 2026Article
- Calciphylaxis diagnosis, management and future directions: a comprehensive update on behalf of the European Renal Association CKD-MBD Working Group.Clinical kidney journal · 2025Review
- Paradoxical effects of parathyroidectomy and sodium thiosulfate in a hemodialysis patient with calciphylaxis: a case report of persistent metastatic calcification.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calciphylaxis is a devastating disease characterized by painful ischemic necrotic skin lesions, primarily affecting patients with end-stage kidney disease. Its incidence has significantly increased over the past decade. Despite substantial morbidity and mortality, the pathogenesis of calciphylaxis remains poorly understood, and currently there are currently no approved treatments available. Diagnosis largely relies on clinical suspicion; skin biopsy may be useful but is not essential, particularly when biopsy risks outweigh benefits. Effective management requires a multidisciplinary approach. Current therapeutic strategies include controlling metabolic bone disease, substituting vitamin K antagonists with alternative anticoagulants, discontinuing calcium and vitamin D supplements, optimizing dialysis protocols, and considering sodium thiosulfate. Promising novel therapies are now emerging. These 10 tips aim to help clinicians avoid common pitfalls and deliver optimal care to patients with calciphylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.